|
1
|
Pourabdollah M and Chang H: Coexistence of
multiple myeloma and Paget disease of bone. Blood. 130:11732017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mai EK, Bertsch U, Durig J, Kunz C, Haenel
M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, et al:
Phase III trial of bortezomib, cyclophosphamide and dexamethasone
(VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in
newly diagnosed myeloma. Leukemia. 29:1721–1729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Issa ME, Takhsha FS, Chirumamilla CS,
Perez-Novo C, Vanden Berghe W and Cuendet M: Epigenetic strategies
to reverse drug resistance in heterogeneous multiple myeloma. Clin
Epigenetics. 9:172017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pawlyn C, Kaiser MF, Davies FE and Morgan
GJ: Current and potential epigenetic targets in multiple myeloma.
Epigenomics. 6:215–228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sanulli S, Justin N, Teissandier A,
Ancelin K, Portoso M, Caron M, Michaud A, Lombard B, da Rocha ST,
Offer J, et al: Jarid2 methylation via the PRC2 complex regulates
H3K27me3 deposition during cell differentiation. Mol Cell.
57:769–783. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pawlyn C, Bright MD, Buros AF, Stein CK,
Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA,
et al: Overexpression of EZH2 in multiple myeloma is associated
with poor prognosis and dysregulation of cell cycle control. Blood
Cancer J. 7:e5492017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cao R, Wang L, Wang H, Xia L,
Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y: Role of
histone H3 lysine 27 methylation in Polycomb-group silencing.
Science. 298:1039–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ito T, Teo YV, Evans SA, Neretti N and
Sedivy JM: Regulation of cellular senescence by polycomb chromatin
modifiers through distinct DNA damage- and histone
methylation-dependent pathways. Cell Rep. 22:3480–3492. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zeidler M, Varambally S, Cao Q, Chinnaiyan
AM, Ferguson DO, Merajver SD and Kleer CG: The polycomb group
protein EZH2 impairs DNA repair in breast epithelial cells.
Neoplasia. 7:1011–1019. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ha K, Lee GE, Palii SS, Brown KD, Takeda
Y, Liu K, Bhalla KN and Robertson KD: Rapid and transient
recruitment of DNMT1 to DNA double-strand breaks is mediated by its
interaction with multiple components of the DNA damage response
machinery. Hum Mol Genet. 20:126–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuroda J: Therapeutic approach for
relapsed/refractory multiple myeloma: The logic and practice.
Rinsho Ketsueki. 58:2058–2066. 2017.(In Japanese). PubMed/NCBI
|
|
12
|
Varga C, Maglio M, Ghobrial IM and
Richardson PG: Current use of monoclonal antibodies in the
treatment of multiple myeloma. Br J Haematol. 181:447–459. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuser-Abali G, Gong L, Yan J, Liu Q, Zeng
W, Williamson A, Lim CB, Molloy ME, Little JB, Huang L and Yuan ZM:
An EZH2-mediated epigenetic mechanism behind p53-dependent tissue
sensitivity to DNA damage. Proc Natl Acad Sci USA. 115:3452–3457.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang
Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, et al: Targeting
NEK2 attenuates glioblastoma growth and radioresistance by
destabilizing histone methyltransferase EZH2. J Clin Invest.
127:3075–3089. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee
YJ, Jiang X, Tan J, Aau M, Lim CZ and Yu Q: Polycomb protein EZH2
regulates cancer cell fate decision in response to DNA damage. Cell
Death Differ. 18:1771–1779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vissers JH, van Lohuizen M and Citterio E:
The emerging role of Polycomb repressors in the response to DNA
damage. J Cell Sci. 125:3939–3948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signalling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Q, Nair S, Laknaur A, Ismail N,
Diamond MP and Al-Hendy A: The polycomb group protein EZH2 impairs
DNA damage repair gene expression in human uterine fibroids. Biol
Reprod. 94:692016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H, Li W, Yu X, Gao F, Duan Z, Ma X,
Tan S, Yuan Y, Liu L, Wang J, et al: EZH2-mediated Puma gene
repression regulates non-small cell lung cancer cell proliferation
and cisplatin-induced apoptosis. Oncotarget. 7:56338–56354.
2016.PubMed/NCBI
|
|
20
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkpoints in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan S, Sorrell M and Berman Z: Functional
interplay between ATM/ATR-mediated DNA damage response and DNA
repair pathways in oxidative stress. Cell Mol Life Sci.
71:3951–3967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang Y, Wang X, Niu X, Wang X, Jiang R,
Xu T, Liu Y, Liang L, Ou X, Xing X, et al: EZH2 suppresses the
nucleotide excision repair in nasopharyngeal carcinoma by silencing
XPA gene. Mol Carcinog. 56:447–463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gursoy-Yuzugullu O, Carman C, Serafim RB,
Myronakis M, Valente V and Price BD: Epigenetic therapy with
inhibitors of histone methylation suppresses DNA damage signaling
and increases glioma cell radiosensitivity. Oncotarget.
8:24518–24532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirk JS, Schaarschuch K, Dalimov Z,
Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili
R and Ellis L: Top2a identifies and provides epigenetic rationale
for novel combination therapeutic strategies for aggressive
prostate cancer. Oncotarget. 6:3136–3146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stamato MA, Juli G, Romeo E, Ronchetti D,
Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P and
Amodio N: Inhibition of EZH2 triggers the tumor suppressive miR-29b
network in multiple myeloma. Oncotarget. 8:106527–106537. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Q: Restoring p53-mediated apoptosis in
cancer cells: New opportunities for cancer therapy. Drug Resist
Updat. 9:19–25. 2006. View Article : Google Scholar : PubMed/NCBI
|
